乌斯特基努马布剂量升级在克罗恩病中的有效性和安全性:一项多中心观察性研究
Raúl Vicente Olmedo Martín1, Juan María Vázquez Morón2, María Del Mar Martín Rodríguez3
1UGC Aparato Digestivo, Hospital Regional Universitario Málaga, España.
Revista espanola de enfermedades digestivas
|June 14, 2023
概括
剂量升级 ustekinumab 有效地恢复了超过一半的克罗恩氏病患者的反应 部分或失去了反应. 这种策略推给那些在标准的乌斯特基努马布维持治疗中无法维持缓解的患者.
科学领域:
- 胃肠病学和肝病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乌斯特基努马布对克罗恩病 (CD) 有效,但一些患者随着时间的推移失去反应.
- 有限的数据存在于ustekinumab剂量升级的CD患者的CD患者与次优反应.
- 确定维持疗效的策略对于管理CD至关重要.
研究的目的:
- 为了评估ustekinumab剂量升级在患有活跃克罗恩病的患者中的有效性.
- 评估剂量强化后的临床反应和缓解率.
- 为了确定升级的ustekinumab剂量的长期维持反应和安全性.
主要方法:
- 对91名患有活性CD的患者进行了回顾性观察性研究 (哈维-布拉德肖指数≥5).
- 患者接受了ustekinumab的诱导和维持,通过更短的间隔或IV再诱导来增加剂量.
- 收集关于临床反应,缓解,皮质类固醇使用和不良事件的数据.
主要成果:
- 乌斯特基努马布剂量升级发生在平均35周后.
- 在升级后16周,62.6%的患者获得了无类固醇临床反应,25.3%的患者获得了缓解.
- 长期随访显示,66.2%的患者持续反应,43.7%的患者缓解;81%的患者仍在服用ustekinumab.
结论:
- 乌斯特基努马布剂量升级是克罗恩病患者恢复反应的有效策略.
- 考虑对患者进行剂量升级,如果患者对标准维持疗法有部分反应或反应丧失.
- 在这个队列中,逐渐增加的剂量表明了有利的安全性和持续的疗效.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
202
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
202
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
161
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
161
Drugs for Treatment of Ulcerative Colitis in IBD
179
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
179
Inflammatory Bowel Disease IV: Pharmacological Management
158
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
158
Inflammatory Bowel Disease II: Crohn's Disease
303
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
303


